Case Presentation {#sec1_1}
=================

An 81-year-old Thai woman with a medical history of hypertension and type 2 diabetes mellitus visited Ramathibodi hospital, Mahidol University, Bangkok, Thailand, with multiple erosions of 4 weeks\' duration. The patient developed blisters on the hands and feet that subsequently expanded to involve the trunk and face. Blisters and erosions occurred on sites of previously uninvolved skin. She also complained of losing both big toe nails. She denied a history of fever, arthralgia, photosensitivity, and a previous or current dermatological condition. Her hypertension and type 2 diabetes had been well-controlled with amlodipine, enalapril, hydrochlorothiazide, and metformin for 6 years. Multiple erosions on erythematous to violaceous patches and plaques on the face, both ears, right axilla, abdomen, distal fingers, and toes with anonychia of both toe nails. Some erosion arose on the normal appearing skin (Fig. [1](#F1){ref-type="fig"}). Histological examination demonstrated subepidermal vesicle with well-preserved dermal papilla associated with dense inflammatory cell infiltration composed of lymphocytes and numerous eosinophils in the papillary dermis. The appearances suggested a subepidermal blistering with lichenoid eruption. A second biopsy on the perilesional skin was done for direct immunofluorescence examination and revealed linear immunoglobulin (Ig) G and C3 deposition along the dermoepidermal junction associated with shaggy deposition of fibrinogen and colloid body of IgM (Fig. [2](#F2){ref-type="fig"}). Enzyme-linked immunosorbent assay (ELISA) for circulating anti-basement antibodies bullous pemphigoid (BP) 180 was positive with a titer of 72.4 (normal value 0--22) and antibody for BP230 was negative. Anti-hepatitis C and hepatitis B antigen were negative. Based on the clinical examination, complete histological and immunological findings as well as the positive ELISA for BP180, the diagnosis of lichen planus pemphigoides (LPP) was made.

Clobetasol proprionate cream 0.05% was commenced for the trunk, extremities, and nails and momethasone furoate cream 0.1% for the face without any improvement. Then, enalapril was discontinued, and 4 weeks later the patient\'s condition moderately improved and was completely cleared at 12 weeks. There was no recurrence after a 12-month follow-up period (Fig. [3](#F3){ref-type="fig"}). The temporal relationship between the use of enalapril and the resolution of the disease upon withdrawal led us to the diagnosis of LPP as a reaction to enalapril.

Discussion {#sec1_2}
==========

LPP is a rare, acquired autoimmune bullous dermatosis. It was introduced by Kaposi in 1982 as a typical case of lichen planus complicated by widespread bullous eruption \[[@B1]\]. The diagnosis of LPP is made by characteristic clinical, histopathological, and immunopathological features.

Clinically, LPP is characterized by an abrupt onset of tense, dome-shaped bullae prior to, during, or after an eruption of lichen planus. The blisters may arise on uninvolved skin or on preexisting lichenoid lesions \[[@B2]\]. In LPP the lesions most commonly involve the distal extremities, but they may occur in a generalized form. Oral and conjunctival mucosa involvement has been reported \[[@B3]\]. LPP more commonly affects males, usually in the fourth or fifth decade of life \[[@B3]\].

Histopathologically, LPP is characterized by typical findings of lichenoid tissue reaction with subepidermal bullae and linear deposits of IgG and C3 along the basement membrane zone (BMZ) on direct immunofluorescence (DIF) of peribullous skin \[[@B4]\]. This patient fulfilled the clinical, histological, and immunofluorescent criteria of LPP. Furthermore, in this patient, DIF revealed classic findings of continuous linear deposition of C3 and IgG and shaggy deposition of fibrinogen along the BMZ.

The pathogenesis of LPP is incompletely elucidated. Some authors hypothesized that a primary inflammatory process by lichen planus causes the release and exposure of hidden antigen leading to a secondary autoimmune response against the BMZ. These circulating autoantibodies induce secondary subepidermal bullous dermatosis. Many cases of LPP reported in the literature have demonstrated IgG antibodies to either one or both BP180 and BP230 antigens \[[@B4]\]. Zillikens et al. \[[@B4]\] demonstrated antibody reactivity in LPP against a novel epitope of region 4 of the NC16A domain of BP180 antigen besides regions 2 and 3.5. This finding was not demonstrated in sera from patients with BP, which indicates that the immunological pattern in LPP differs from that in patients with BP \[[@B4]\]. BP180 ELISA using a commercial kit was positive in our patient.

LPP has been reported to be induced by medications such as angiotensin-converting- enzyme inhibitors (captopril \[[@B5], [@B6]\], ramipril \[[@B7], [@B8]\]), cinnarizine \[[@B9]\], PUVA \[[@B10]\], simvastatin \[[@B11]\], Chinese herb \[[@B12]\], weight reduction product \[[@B13]\], and NB-UVB \[[@B14]\]. The interval between drug administration and occurrence of LPP ranged from 2 to 24 weeks. Like drug-induced lichen planus and lichenoid drug reaction, an extended time interval between the initiation of the drug to the onset of symptoms does not exclude a potential diagnosis of drug-induced LPP \[[@B15]\]. For most patients, the skin eruptions resolved within a few weeks after withdrawal of the drug (Table [1](#T1){ref-type="table"}). The definitive proof of diagnosis is recurrence on challenge, but this is not always possible or desirable.

Low to moderate doses of oral corticosteroid seems to be effective in the majority of patients with LPP. In some cases, topical corticosteroid administration alone was shown to be effective. There is little information about therapy with other immunosuppressant drugs or combination with corticosteroid for LPP \[[@B3]\]. In our case, a potent topical corticosteroid was not effective. The patient had gradual improvement and established complete resolution upon cessation of the culprit medication.

The prognosis of LPP tends to be better compared to BP and lichen planus. The average rate of recurrence was about 20% and the response after treatment was about 1--12 months, which appears to be lower when compared to BP and lichen planus.

To our knowledge, this is the first case report of enalapril associated with the development of LPP. Early recognition and prompt discontinuation of the possible medication allows improvement of the clinical outcome and prevents further complications.
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![Multiple erosions on erythematous to violaceous patches and plaques involving bilateral ears (**a**, **b**), abdomen (**c**), distal fingers (**d**), and toes with anonychia of both toe nails (**e**).](cde-0009-0217-g01){#F1}

![Linear IgG (**a**) and C3 (**b**) along the dermoepidermal junction. Moderate cytoid body IgM (**c**) associated with shaggy deposition of fibrinogen (**d**) along the dermoepidermal junction.](cde-0009-0217-g02){#F2}
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###### 

Drug associated with lichen planus pemphigoides

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medications                Authors \[Ref.\], year               Onset      Cutaneous distribution         Mucosa   Additional treatment           Time of resolution and recurrence
  -------------------------- ------------------------------------ ---------- ------------------------------ -------- ------------------------------ ----------------------------------------------------------------------------------------------------
  ACE inhibitor\             Our case                             6 years    Trunk, extremities             No       Topical steroid                12 weeks, no recurrence after 1-year follow-up
  - Enalapril\                                                                                                                                      
  - Captopril\                                                                                                                                      
  - Ramipril                                                                                                                                        

                                                                                                                                                    

                             Flageul et al. \[[@B6]\], 1986       2 weeks    Extremities                    No       Topical steroid                Not completely resolved at 10-month follow-up

                                                                                                                                                    

                             Ben Salem et al. \[[@B5]\], 2008     2 weeks    Trunk, extremities             No       Systemic steroid               4 weeks, no recurrence after 8-month follow-up

                                                                                                                                                    

                             Ogg et al. \[[@B7]\], 1996           4 weeks    Trunk, extremities             No       Systemic steroid               9 weeks, no recurrence after 1-year follow-up

                                                                                                                                                    

                             Zhu et al. \[[@B8]\], 2006           3 weeks    Trunk, extremities             Yes      No                             4 weeks

                                                                                                                                                    

  Cinnarizine                Miyagawa et al. \[[@B9]\], 1985      12 weeks   Lower extremities then trunk   No       Griseofulvin                   12 weeks

                                                                                                                                                    

  PUVA                       Kuramoto et al. \[[@B10]\], 2000     24 weeks   Trunk, extremities             No       Systemic and topical steroid   4 weeks, no recurrence after 1-year follow-up

                                                                                                                                                    

  Simvastatin                Stoebner et al. \[[@B11]\], 2003     4 weeks    Trunk, extremities             No       Topical steroid                4 weeks

                                                                                                                                                    

  Chinese herb               Xu et al. \[[@B12]\], 2008           8 weeks    Trunk, extremities             Yes      Systemic steroid and dapsone   Not completely resolved at 2-year follow-up (remains on dapsone and intermittent topical steroids)

                                                                                                                                                    

  Weight reduction product   Rosmaninho et al. \[[@B13]\], 2011   8 weeks    Trunk, extremities             No       Dapsone                        4 weeks, no recurrence during 1-month follow-up
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACE; angiotensin-converting enzyme.
